Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Attractive 2: PK of ATR-258 Capsule vs Solution
NCT06432673Phase 1Completed
- Sponsor
- Atrogi
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ATR-258 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Atrogi. Primary endpoints: Area under the plasma concentration versus time curve at 48 hours and Peak Plasma Concentration at 48 hours. Started Apr 2024; status: completed.
02
Drugs
ATR-258
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06432673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06432673.